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Background: A recent HTA review concluded that there was a need for RCTs of exercise referral schemes (ERS) for
people with a medical diagnosis who might benefit from exercise. Overall, there is still uncertainty as to the cost-
effectiveness of ERS. Evaluation of public health interventions places challenges on conventional health economics
approaches. This economic evaluation of a national public health intervention addresses this issue of where ERS
may be most cost effective through subgroup analysis, particularly important at a time of financial constraint.
Method: This economic analysis included 798 individuals aged 16 and over (55% of the randomised controlled trial
(RCT) sample) with coronary heart disease risk factors and/or mild to moderate anxiety, depression or stress.
Individuals were referred by health professionals in a primary care setting to a 16 week national exercise referral
scheme (NERS) delivered by qualified exercise professionals in local leisure centres in Wales, UK. Health-related
quality of life, health care services use, costs per participant in NERS, and willingness to pay for NERS were
measured at 6 and 12 months.
Results: The base case analysis assumed a participation cost of £385 per person per year, with a mean difference in
QALYs between the two groups of 0.027. The incremental cost-effectiveness ratio was £12,111 per QALY gained.
Probabilistic sensitivity analysis demonstrated an 89% probability of NERS being cost-effective at a payer threshold
of £30,000 per QALY. When participant payments of £1 and £2 per session were considered, the cost per QALY fell
from £12,111 (base case) to £10,926 and £9,741, respectively. Participants with a mental health risk factor alone or in
combination with a risk of chronic heart disease generated a lower ICER (£10,276) compared to participants at risk
of chronic heart disease only (£13,060).
Conclusions: Results of cost-effectiveness analyses suggest that NERS is cost saving in fully adherent participants.
Though full adherence to NERS (62%) was higher for the economics sample than the main sample (44%), results
still suggest that NERS can be cost-effective in Wales with respect to existing payer thresholds particularly for
participants with mental health and CHD risk factors.
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Lack of adequate physical exercise is a contributing fac-
tor in CHD risk, musculoskeletal problems, diabetes and
depression which places a huge economic burden on the
NHS and wider society in the UK [1] with similar trends
worldwide. There is growing interest in general practice
(GP) exercise referral schemes. Referred patients access
an individually tailored exercise programme, including;
exercise classes, swimming, green gyms and yoga.
Economic evaluation of public health interventions
places challenges beyond the economic evaluation of
clinical interventions in terms of potential wider bene-
fits, multiple stake holders bearing costs, and time hori-
zons over which costs and benefits will be accrued [2,3].
It is helpful to view such public health interventions as
complex interventions with multiple components (in this
case, fidelity to specific exercise interventions, compli-
ance (dose) and uptake of the intervention, and mecha-
nisms of behaviour change) [4,5].
Internationally, cost-effectiveness evidence has been
equivocal compared with other population level inter-
ventions [6]. Matrix (2006), [7] reviewed the literature
and modelled the cost-effectiveness of four interven-
tions, pedometers, exercise referral, walking and cycling
programmes in the community. Cost per QALY esti-
mates for all four interventions were well below the
NICE threshold of £20,000 to £30,000 per quality ad-
justed life year (QALY). Pavey et al. (2011), [8] showed a
51% probability of GP referral being cost-effective at
£20,000 per QALY, 88% at £30,000 per QALY. In
Australia, Cobiac et al. (2009), [6] modelled disability ad-
justed life years (DALYs) gained from six population
level exercise promotion interventions. They found that
pedometer use, mass media-based community campaigns,
GP exercise referral, healthy transport and internet pro-
grammes were within the AUS $50,000 threshold.
There have been few prospective economic evaluations
alongside pragmatic, community based RCTs of GP
exercise referral schemes. Munro et al. (2004), [9] calcu-
lated a cost per QALY of €17,174 for a community-
based exercise programme in over 65 year olds. Owen
et al. (2011), [10] published a list of 200 public health in-
terventions included in NICE guidance, of which exer-
cise referral was one of the 85% of interventions under
the £20,000 threshold. The above authors do not explore
cost-effectiveness with respect to subgroups or explore
how interventions address known inequalities in health,
points recognised by Kelly et al. (2005) and Weatherly
et al. (2009), [2,3]. In particular, how effective and cost
effective ERS are for participants with a medical diagno-
sis which may benefit from exercise [8].
This economic evaluation was conducted alongside a
pragmatic randomised controlled trial of the Welsh
National Exercise Referral Scheme (NERS) [11,12].Detailed effectiveness and headline economic results are
published elsewhere [12]. NERS was designed to encour-
age increased activity in patients at low or medium risk
of coronary heart disease or with mild to moderate de-
pression. The scheme was sponsored by the Welsh
Government (WG) in partnership with local authorities,
National Public Health Service and Local Health Boards.
The aim of our economic evaluation was to assess the
cost-effectiveness of NERS in Wales from a multi-
agency public sector perspective and to use subgroup
analysis to explore the effects of medical diagnosis, gen-
der, age, inequalities, referral route and adherence on
effectiveness and cost-effectiveness.
Methods
Study design
A pragmatic, randomised controlled trial, with nested
economic evaluation was conducted in 12 of the 22 local
health board (LHB) areas in Wales, UK (for full details
see study protocol) [11,12]. Participants aged >16 years,
sedentary with risk factors for coronary heart disease
(CHD) or minor mental health problems, were recruited
by health professionals in primary care and randomised
to intervention or control group. The intervention group
participants were offered a 16-week exercise programme
delivered by qualified exercise professionals (EP) based
in local authority leisure centres. Participants allocated
to the control group received an information leaflet and
preferential access to the scheme after 12 months.
Data collection and economic measures
Postal questionnaires were sent to all participants at
baseline, 6 and 12 months. The questionnaire at
12 months included a willingness to pay question. Non-
respondents received a reminder two weeks later. The
Client Service Receipt Inventory [13] asked participants
to recall their recent contacts with health care services
in primary and secondary care, including prescribing.
EQ-5D (3 L) [14] is a generic, preference based instru-
ment for evaluating health-related quality of life. A min-
imal questionnaire pack was sent at baseline assessing
demographics and activity levels to reduce participant
burden and facilitate recruitment.
Intervention costs
A breakdown of the budget for NERS for 13 local au-
thorities initially providing NERS was obtained from
WG. This budget included 50% of local authority exer-
cise coordinators’ salaries, 100% of leisure centre exer-
cise professionals’ (EP) salaries, training; promotional
materials, administration, information technology, travel
and equipment. Telephone interviews with NERS
programme directors at WG and leisure centre man-
agers were conducted to capture additional costs
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did not implement the scheme during the trial period.
Cost and cost-effectiveness analysis
The mean national and local authority cost of running
NERS for one year was used to calculate the range of
costs and a cost per participant in the Scheme. We var-
ied our assumptions around the number of referrals
based on three estimates of participation;
a. referrals to the trial from July 2007 to October 2008,
(n = 4779);
b. participants who accessed NERS during the trial,
those in the intervention group (n = 1080) plus
people referred to NERS, but not eligible for the trial
(n = 1493), minus an estimated 15% who would not
attend, (n = 2349).
c. and an arithmetic mean between our upper and
lower estimates, (n = 3530).
The cost of the participants’ resource use was estimated
in UK £, cost year 2008 using national sources [15-17].
Cost-utility analysis was conducted in line with MRC
guidelines for the evaluation of complex interventions, [4]
and our standard operating procedure for economic evalu-
ation alongside pragmatic RCTs, [18]. When EQ-5D, [14]
data was missing for one or two domains in the five domain
scale, stochastic imputation (assuming data was missing at
random) was used (n = 28 scores). Since health-related
quality of life was assessed at 6 and 12 month follow-up
only, the base-case analysis used area under the curve
(AUC) data for the period between 6 and 12 months to esti-
mate QALY change. Sensitivity analyses were conducted
using: a) EQ-5D, [14] scores at 6 months for both interven-
tion and control group as an estimate of baseline differ-
ences, and b) using control group mean EQ-5D scores at
6 months as a point estimate of EQ-5D, [14] score at base-
line. Sensitivity analyses were conducted for: different inter-
vention costs (£285, £385 and £579); referral to NERS by
GP, nurse, or 50% referral by GP and 50% by nurse; partici-
pant payment of £1 per session, and of £2 per session
(taking into account Wales Index of Multiple Deprivation;
WIMD). Subgroup analyses compared the cost-effectiveness
of NERS depending on gender, age group (<44, 44–60
or >60 years), adherence to the Scheme (16 weeks
or <16 weeks), and referral reason (CHD and/or mental
health risk factors). Cost-utility analyses were carried out
using STATA SE 10. Costs and benefits were not discounted
as the trial follow-up period was 12 months.
Results
Characteristics of economic sample
The economic sample, for whom full cost and EQ-5D,
[14] data were collected (n = 798), represented 55% ofthe main effectiveness trial sample [12]. There were no
statistically significant differences between the two sam-
ples with regard to gender of participants, or the WIMD
[19]. However, the economic sample contained fewer
younger participants (18%) than the effectiveness sample
(30%), and a higher proportion of individuals who were
referred because of CHD risk (77%) compared to the
main sample (71%). There were no significant differ-
ences between the control and intervention groups in
the economic sample with regard to demographic char-
acteristics, levels of physical activity at baseline, referral
reasons, and the mean number of reported visits to
health professionals in the previous six months
(Additional file 1: Table S1).
The cost of the national exercise referral programme
Table 1 shows the total set up and annual operating
costs of the NERS. Setup costs included salaries, meet-
ings, printing and resources, translation costs and train-
ing for exercise professionals. Costs incurred by WG for
the 6 pilot areas in 2006–07 are included as part of
NERS development costs (£183,600). The estimated total
setup costs incurred by the WG were £365,875; mean
cost per local authority £28,144. Annual operating costs
for NERS in 2007/08 was £1.36 million, mean per local
authority was £104,602 (SD £27,226). Operating costs
are inclusive of salaries for coordinators, exercise profes-
sionals, printing, administration, travel, staff manage-
ment, additional training and room hire.
On an intention-to-treat basis, to estimate the cost per
participant in NERS, we divided the total annual operat-
ing costs for NERS for 2007/08 (£1,359,832), by 52
(weeks), multiplied by 16 (16 week programme), then di-
vided this figure by the three estimates of number of re-
ferrals to NERS across the participating local authorities.
We report a base case ICER calculation using the mid
point estimate of the cost per participant (£385,
n = 3530), in addition to an upper (£579, n = 2349) and
lower estimate (£285, n = 4779), (Table 1).
Opportunity costs
Leisure centre managers reported no lost revenues from
providing NERS, as sessions were held at quieter times
of the day, thus utilizing underused space.
Use of health services
National unit costs of health services used in the calcula-
tions can be accessed as Additional file 2: Table S2. Table 2
shows the frequency and total mean costs of service use by
intervention and control groups, subdivided into primary
care (including prescribing) and secondary care. For the
12 month study period there was no significant difference
in NHS resource use between the intervention and control
Table 1 NERS set up costs for 13 local authorities in
Wales in 2006–08 and operational costs for 2007–08
based on national budget plus national and local
authority additional costs (£)1
2006-08 Total (£) Mean
(per LA)
S.D.
Set up
National costs
Salaries
Physical activity specialist
(0.2 WTE in yr 1, 0.6 WTE yr 2)
39,317
Line Management
(0.02 WTE yrs 1&2 Grade 7)
5,823
Executive officer (0.2 WTE yr 2) 4,254
Exercise professionals training (Level 3) 51,759
Meetings 3,852
Resources & printing 9,845
Translation costs 537
Pilot exercise referral project 183,587
Additional Local Authority costs
IT 43,004 3,308 1,775
Equipment 15,290 1,176 874
Staff clothing 1,196 92 218
Attending meetings 4,030 310 506
Promotion or advertising 2,210 170 316
Home working facilities 1,170 90 246
Total set up 365,875 28,144 2,475
Annual operational costs 2007-08
National costs
WAG salaries
Physical activity specialist (0.8) 39,298
Line Management
(0.02 WTE Grade 7)
3,515
Executive officers (1.2 WTE) 26,618
Meeting costs 2,855
National resources 20,324
Exercise professionals (36 WTE) 781,833 60,141 24,213
Printing, stationary and administration 19,750 1,646 829
Training 18,967 1,459 916
Travel 47,351 3,642 1,496
Joint national and local costs
Co-ordinator salary and on-costs
(13 WTE 50% funded by WAG & LA)
358,574 27,583 3,995
Local authority costs
Staff management 29,250 2,250 n/a
Promotional material 715 55 151
Room hire 10,326 794 1,453
Attending conferences 455 35 96
Table 1 NERS set up costs for 13 local authorities in
Wales in 2006–08 and operational costs for 2007–08
based on national budget plus national and local
authority additional costs (£)1 (Continued)
Total NERS annual operational cost £1,359,832 104,602 27,226
Cost per participant in NERS N or £
Participants in NERS (N)2 2,349
Participant cost in 16 week
programme based on intervention
group3
£579
All referrals July 2007 – October 2008
(12 months in study period) (N)
4,779
Participant cost in 16 week
programme3
£285
Arithmetic mid-point between referrals
and participants
3,530
Base case intervention per person
cost using N above
£385
Participants in the economic analysis
who supplied service utilisation data
798
1All costs in UK£ rounded to nearest whole £.
2People who accessed NERS during the trial, those in the intervention group
(n=1080) plus the people referred who were eligible for NERS but not for the
trial, minus 15% non-attenders (n=1493), a total of 2349.
3Calculation - total annual operational cost divided by N.
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the control group (p = <0.05).
Adherence to NERS
Approximately 62% completed the 16 week programme,
32% (n = 123) attended fewer than 16 weeks, and 8%
(n = 30) did not attend at all. Table 3 breaks down ad-
herence by reason for referral, gender, age and the
WIMD, [19]. Those at risk of CHD were more likely to
adhere to the full programme than those with mental
health problems, and those with both mental health
problems and at risk of CHD. A higher percentage of
men completed the programme than women. Those
people living in areas of high deprivation were more
likely to complete the programme (66%) compared with
those living in areas of low deprivation (60%).
Participants’ willingness to pay for exercise classes
At 12 month follow-up, 55% completed the willingness
to pay question (n = 441). The amount people were
willing to pay was £2.16 (SD £1.50) for those in the
intervention group compared with £2.38 (SD £1.78) in
the control. This had fallen from the baseline figure of
£2.43 (SD £1.67) compared with £2.55 (SD £2.49) in the
control (81% response, n = 648). There was a difference
in willingness to pay (WTP) depending upon whether
people lived in an area of low or high deprivation as
measured by the WIMD. At 12 month follow-up people
from areas of high deprivation were WTP £1.91 (SD
Table 2 NERS resource use and costs over 12 months by group
Intervention group Control group Significance1
n=400 n=398 P
Primary Care Sector Mean, median (min, max)
GP consultations, surgery 5.18, 4 (0, 28) 6.00, 5 (0, 46) 0.11
Phone 0.63, 0 (0, 14) 0.69, 0 (0, 20) 0.68
Home visits 0.12, 0 (0, 20) 0.11, 0 (0, 10) 0.64
Practice nurse consultations 2.98, 1 (0, 29) 3.31, 2 (0, 42) 0.05
Mental Health Professionals 0.83, 0 (0, 32) 0.71, 0 (0, 53) 0.58
Other health professionals 0.65, 0 (0, 32) 1.14, 0 (0, 36) 0.11
Secondary Care Sector
Consultant 2.00, 1 (0, 22) 2.09, 1 (0, 26) 0.55
Specialist nurse 0.87, 0 (0, 42) 0.61, 0 (0, 24) 0.98
Physiotherapist 1.59, 0 (0, 52) 1.66, 0 (0, 48) 0.63
Other health professionals seen 0.68, 0 (0, 78) 0.35, 0 (0, 26) 0.21
A&E 0.32, 0 (0, 18) 0.30, 0 (0, 15) 0.08
Inpatient hospital days (all causes) 0.97, 0 (0, 96) 1.05, 0 (0, 32) 0.70
Type of Cost2 Intervention Control group Mean difference
Mean (SD) Mean (SD) (95% CI bootstrapped)
NHS primary care sector
GP consultations:
Surgery 186 (159) 215 (204) −28
Telephone 14 (36) 15 (40) −1.4
Home visits 6 (55) 6 (35) 0.7
All GP consultation (subtotal) 206 (182) 235 (224) −29 (-59, -0.3)
Practice nurse consultations 51 (104) 56 (125) −5
Mental health professional 42 (189) 36 (198) 6
Other health professionals 23 (87) 31 (121) −9
Total primary care consultations 322 (339) 358 (409) −36.5 (-92, 16)
Primary care prescribing 352 (448) 391 (494) −39
Total primary care 674 (610) 749 (712) −76 (-167, 14)
NHS secondary sector
Outpatients:
Consultant 223 (302) 232 (325) −9 (-51, 33)
Specialist nurse 312 (127) 21 (69) 11 (-2, 24)
Physiotherapist 65 (223) 68 (202) −3 (-31, 26)
Other hospital attendances 60 (598) 17 (107) 43 (-3,110)
Day cases 121 (361) 83 (330) 38 (-12, 89)
Inpatient hospital days (all causes) 374 (1915) 411 (1447) −37 (-246, 210)
A&E attendances 26 (107) 23 (78) 2 (-10, 16)
Tests 121 (251) 149 (258) −28 (-64, 7)*
Total secondary care 901 (2235) 856 (1721) 45 (-208, 351)
TOTAL NHS COST 1695 (2514) 1754 (2155) −58.4 (-361, 301)
Base case NERS Intervention cost
2 session/week for 16 week 385 0 (0) 385
TOTAL NHS, WAG and LOCAL AUTHORITY COST 2080 (2514) 1754 (2155) 326 (-2, 660)
1Mann–Whitney test (exact two-sided significance level) No significant differences found.
2Costs rounded to nearest £.
*The difference is significant (P < 0.05) according to Mann–Whitney test.
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Table 3 Mean effectiveness outcomes by group over 12 months
Outcomes at 12 month follow-up Intervention group Control group Significance*
Mean (SD) Mean (SD) p
**EQ5D score (0-1) 0.64 (0.32) n=395 0.61 (0.32) n=391 0.09
Exercise per week 305.96 min (386.5) n=298 305.8 min (393.3) n=279 0.7
Adherence
Did not attend 30 (8%)
Attended <16 wks 123 (32%)
Attended 16 wks 247 (62%)
Level of adherence to NERS by variable Did not attend 0-16 week Completed
N (%) N %) N (%)
Referral type CHD risk 20 (7) 84 (27) 203 (66)
MH 0 4 (31) 9 (69)
Both 10 (12) 35 (44) 35 (44)
Gender Male 15 (11) 31 (33) 89 (66)
Female 15 (5) 92 (35) 158 (60)
Age <44 5 (7) 25 (36) 39 (57)
45-59 10 (7) 50 (27) 75 (56)
>60 15 (8) 48 (24) 133 (68)
WIMD Low 7 (5) 49 (35) 84 (60)
Medium 13 (10) 37 (28) 84 (63)
High 9 (8) 29 (26) 73 (66)
*The difference is significant (p <0.05) according to Mann–Whitney test.
**EQ-5D (L3).
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deprivation. Similarly, in the control group people were
willing to pay £2.09 (SD £1.53) and £2.32 (SD £1.78),
respectively. In all groups people valued the intervention
more highly if they were in the control group. When
considering the WTP by employment status then stu-
dents were willing to pay the most per session and
those seeking work the least.
Cost-utility analysis
The base case analysis produced a mean difference in
cost of £327 and a mean difference in QALY gains of
0.027 between groups, indicating NERS was more ex-
pensive and more effective compared to the control. The
incremental cost-effectiveness ratio (ICER) was £12,111
per QALY gained. Figure 1 shows the cost-effectiveness
plane with 1,000 bootstrapped ICER estimates. The
figure demonstrates that the majority of simulations fell
in the north-east quadrant of the cost-effectiveness
plane, where the intervention is more expensive and
more effective compared to the control condition.
Sensitivity analyses
Probabilistic sensitivity analysis conducted for our base case
demonstrated that there is a 77% probability of NERS being
cost-effective at £20,000 per QALY and 89% at £30,000 perQALY gained (Table 4). To assess the uncertainty associ-
ated with cost of NERS, sensitivity analyses were performed
assuming an annual cost of attending the programme of ei-
ther £285 or £579 per person per year. The ICER point esti-
mates were £8,556 and £19,296 per QALY, respectively,
remaining below a £30,000 payer threshold. However, for
an annual cost of attending the NERS programme of £579
per person, the probability of the scheme being cost-
effective was lower than the base case at 54% and 70% at
£20,000 and £30,000 thresholds, respectively.
When EQ-5D, [14] data at 6 months was used as an esti-
mate of baseline EQ-5D scores, the difference in QALY
gain between the intervention and control groups was
0.054, resulting in a decrease in ICER estimate from
£12,111 to £6,056. Using the control group mean EQ-5D,
[14] score at 6 months as an estimate of baseline values for
both intervention and control groups, produced a QALY
difference of 0.046 and an ICER point estimate of £7,109.
Probabilistic sensitivity analyses demonstrated that alterna-
tive methods of QALY calculation resulted in higher prob-
abilities of NERS being cost-effective compared to our base
case, which can be considered conservative (Table 4).
Pragmatic sensitivity analyses were conducted to com-
pare referrals to NERS by a GP or a nurse. When all pa-
tients were referred by a GP this resulted in a higher
ICER (£13,444) compared to referral by nurse (£12,667)
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Figure 1 Cost-effectiveness planes with 1,000 bootstrapped ICER estimates for NERS economic evaluation. Cost-effectiveness planes for
base case (A), cost-effectiveness acceptability curves for three intervention costs of £285, £385 (base case) and £579 (B), and for participant
subgroups with different referral reason to NERS (C), adherence to NERS (D), gender (E), and age of participants (F).
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ing cost-effective was 72%,76% and 75% respectively at
£20,000 threshold; and 87%, 89% and 88% respectively at
£30,000 threshold). When participant payments of £1
and £2 per session were considered in the cost-utility
analysis, the cost per QALY fell from £12,111 to £10,926
and £9,741, respectively. The probability of NERS being
cost-effective at £30,000 per QALY increased from 89%
to 91% and 92%, with the £1 and £2 per session partici-
pants’ contributions (Table 4).
Subgroup analyses
Since the participant sample used in our cost-utility
analysis was heterogeneous with relation to age (16–88 years), gender, reason for referral and adherence to
NERS, a range of subgroup analyses were conducted to
identify population groups which would most benefit
from joining the NERS Scheme (Table 4). The cost-
effectiveness acceptability curves (CEACs), (Figure 1C-F)
demonstrated NERS is more likely to be cost-effective in
younger participants (<44 years) than in older individ-
uals. Participants with a mental health risk factor alone
or in combination with a risk of chronic heart disease
were characterized by a lower ICER (£10,276) compared
to participants at risk of chronic heart disease only
(£13,060). Subgroup analysis by gender, gave a signifi-
cantly lower ICER for women (£9,006) than for men
(£38,333). Pronounced differences in ICER were found
Table 4 Results of cost-utility analysis
Incremental
cost (£)
Incremental
QALY
ICER point estimate (£)
(Bootstrapped one
sided 95% CI for
ICER (£))
Probability
intervention is cost-
effective at £20,000
per QALY (%)
Probability
intervention is cost-
effective at £30,000
per QALY (%)
Base case
Cost of intervention £385 327 0.027 12,111 (58,881) 77 89
Sensitivity analysis
EQ-5D at 6 months as estimate of baseline 327 0.054 6,056 (37,159) 93 96
Control group mean
EQ-5D at 6 months as estimate of baseline
327 0.046 7,109 (24,853) 95 98
Participant payment of £1 per session 295 0.027 10,926 (69,085) 80 91
Participant payment of £2 per session 263 0.027 9,741 (64,638) 83 92
Subgroup Analysis
Referral reason 239 0.0183 13,060 (117,893) 65 76
CHD 596 0.058 10,276 (50,925) 80 89
Mental health and CHD plus mental
health
Gender
Male 322 0.0084 38,333 (254,973) 39 47
Female 326 0.0362 9,006 (39,000) 85 95
Age
<44 68 0.0656 1,037 (16,418) 98 99
44-60 577 0.0179 32,235 (314,108) 37 51
>60 244 0.0187 13,048 (153,565) 67 76
Adherence to NERS
<16 weeks 662 −0.0084 Dominated 2.9 5.6
16 weeks -18 0.049 Dominant 100 100
N/A, not applicable.
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fewer than 16 sessions (Table 4). For participants adher-
ing to NERS, the analysis resulted in a net saving of £18
per patient per year. The probability that NERS is cost-
effective in adherent participants was 100% at £20,000
(Figure 1).
Discussion
The main trial effectiveness findings [12] demonstrated
that the NERS was effective in increasing weekly exer-
cise and improved self-reported mental health at
12 months as compared to the control group. A larger
effect was found for women versus men and for persons
who completed the 16 week programme, as compared
with those who were non-adherent. Results of cost-
effectiveness analyses suggest that NERS is likely to be
cost saving in fully adherent participants [8]. Our base
case analysis and sensitivity analyses, we see that the
ICER for NERS under different assumptions falls largely
below a payer threshold of £20-30,000. However we
recognize the need for caution in interpretation of ICERs
which have an upper 95% confidence limit above£20,000 (Table 4). From a methodological viewpoint, the
NERS trial shows the benefits of incorporating subgroup
analysis and analysis of how public health interventions
may impact on inequalities in health through i.e.
differing uptake and effects by women and men, and
differing willingness to pay by areas of socioeconomic
deprivation. Our conservative base case analysis is ro-
bust to a range of sensitivity analyses, leading to the
conclusion that NERS is likely to be cost-effective, under
the £20,000 to £30,000 threshold (89% probability at
£30,000).
Decisions based on average measures of cost-
effectiveness carry a risk of overlooking potential bene-
fits for a given subset of the population. In the current
climate of limited health care resources, there is a clear
necessity to maximise population health by delivering
healthcare interventions to those recipients who would
most benefit, [19]. The proposed ways to account for
heterogenity between population groups included:
reporting ICER estimates for different subgroups, in-
corporating covariate adjustment in cost-effectiveness
analysis, and using alternative cost-effectiveness indicators,
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between subgroups.
Our analysis shows that adherence to exercise was
greater in those areas of high deprivation as measured
by the WIMD, [19]. We also found that those people liv-
ing in areas of high deprivation placed a higher value on
NERS than those living in areas of lower socioeconomic
deprivation. Our study goes some way to address current
thinking in public health economics about the need to
consider equity implications of access and uptake, in
addition to cost-effectiveness, [10].
Comparison with other literature
Economic evaluation of exercise referral schemes involv-
ing inactive adults in primary care have been conducted
as a part of the NIHR Health Technology Assessment
programme, [12]. The base-case cost-effectiveness ana-
lysis of NERS in Wales generated comparable data with
previous reports, [6-9,25] demonstrating that the exer-
cise referral schemes may be cost-effective under the
£30,000 per QALY threshold. However, lifetime model-
ling exercises indicate a greater uncertainty of the long
term cost-effectiveness of such programmes, [26]. Our
study suggests that NERS would be also be cost-effective
in individuals at risk of CHD and mental health issues,
as well as in individuals aged 60 years and over. The
NERS may be cost-saving assuming full adherence to the
programme.
Strengths and limitations
There have been few rigorous prospective economic
studies alongside RCTs of exercise referral interventions.
Results of the NERS trial, as a pragmatic policy evalu-
ation, are likely to have high external validity and gener-
alisabilty, [27]. Full details of the methodological design
of the NERS trial and its acknowledged limitations are
published elsewhere, [11,12]. The NERS trial set out to
explore the potential effectiveness and cost effectiveness
of a national exercise referral scheme, integrating motiv-
ational interviewing, and making use of existing leisure
centres. The NERS trial took a pragmatic approach, in
that it was powered to show a difference in reported ex-
ercise at 12 months, by telephone, using 7D-PAR, a well
validated measure, rather than focussing on load i.e. ex-
ercise type, or intensity. The NERS trial did focus on pa-
tients with CHD risk factors, mental health problems or
both, but did not specify exercise type. Indeed the exer-
cise was tailored, and this tailoring may explain the rela-
tively high adherence rate to the programme. The NERS
trial differs from published trials of specific exercise pro-
grammes for people with specific diagnoses, and hence
economic evaluation of the NERS trial in terms of cost-
utility analysis differs from cost-utility analyses of spe-
cific exercise programmes for people with specificdiagnoses, [28]. The trial specifically recruited patients
with CHD risk factors, mental health problems or both
conditions. The trial found that NERS was effective in
increasing physical activity among those referred with
CHD risk factors. Although there was no increase in
physical activity among those referred for mental health
reasons, anxiety and depression were reduced. These
effects were highly dependent on adherence to the
programme. To these results [12], this paper adds cost
per QALY estimates for NERS, for comparison with
payer thresholds, such as that of NICE, and for compari-
son with those of other large, community based ERS,
[25]. The NERS trial allowed a fully integrated economic
evaluation which took a wide perspective, measuring
costs and benefits to the WG, local authority leisure
centres as well as the NHS. To reiterate, the methodo-
logical design of the NERS trial was more about achiev-
ing external validity in terms of policy evaluation at a
macro level, than about micro level evaluation of a spe-
cific exercise programme for a specific diagnosis or pa-
tient group, in a sports science context.
A limitation of our study was that baseline EQ-5D,
[14] data was not available. However, on the small set of
baseline measures which were taken, activity level, ser-
vice use over the preceding 6 months, age and gender,
the intervention and control groups were similar. Our
economic analysis was based on a smaller number of
participants, because not all participants completed the
economic questionnaires. We acknowledge that using a
smaller number of participants in subgroup analysis in-
creases statistical uncertainty. Reported ICER point esti-
mates have a rather explorative value and require further
verification.
We cannot extrapolate beyond the 12 month follow
up period of the trial which is a limitation common to
many trials of public health interventions. A future mod-
eling exercise may help address the question of whether
such an exercise intervention could have longer term
benefits.
The effectiveness and economic results of the NERS
trial suggest that age, gender and adherence all have an
important part to play in affecting weekly exercise be-
haviour and self reported, health related quality of life.
Weatherly et al. (2009), [3] have stressed the need for
economic evaluations of public health interventions to
examine equity considerations. Our results indicate that
people living in areas of higher deprivation who were
offered NERS were likely to adhere to the complete
programme, although more research would be needed to
investigate if this was maintained in the long-term.
Conclusions
Though full adherence to NERS (62%) was higher for
the economics sample than the main sample (44%), our
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robust to a range of sensitivity analyses. ICERs were well
below the NICE threshold of £20-30,000, though upper
95% confidence limits cross this boundary, indicating
the need for caution in the interpretation of results.
There is evidence for confidence that NERS is likely to
be cost saving in fully adherent participants, leading to
the overall conclusion that NERS can be cost-effective.
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